Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan

[1]  Wei Liu,et al.  Effectiveness and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir as a Hepatitis C Virus Infection Salvage Therapy in the Real World: A Systematic Review and Meta-analysis , 2022, Infectious Diseases and Therapy.

[2]  Y. Wong,et al.  Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor‐experienced patients with hepatitis C: Real‐world data from a multicenter Asian registry , 2022, Journal of gastroenterology and hepatology.

[3]  Jessica R. Ackerman,et al.  Retreatment for hepatitis C virus direct‐acting antiviral therapy virological failure in primary and tertiary settings: The REACH‐C cohort , 2022, Journal of viral hepatitis.

[4]  T. Tseng,et al.  Long-term evolution of estimated glomerular filtration rate in patients with antiviral treatment for hepatitis C virus infection. , 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  Jisoo A. Kwon,et al.  Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. , 2022, The lancet. Gastroenterology & hepatology.

[6]  S. Flamm,et al.  Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[7]  M. Vachon,et al.  Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  J. Kao,et al.  Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan , 2021, Hepatology International.

[9]  M. Hellard,et al.  Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics. , 2020, Clinical Infectious Diseases.

[10]  J. Pawlotsky,et al.  EASL recommendations on treatment of hepatitis C - Final update of the series. , 2020, Journal of hepatology.

[11]  Ding‐Shinn Chen,et al.  Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan. , 2020, Journal of the Formosan Medical Association = Taiwan yi zhi.

[12]  D. Dieterich,et al.  Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus. , 2020, European journal of gastroenterology & hepatology.

[13]  I. Ntalla,et al.  Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[14]  F. Negro,et al.  Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis. , 2020, Journal of hepatology.

[15]  F. Girardin,et al.  Direct‐acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV‐infected patients , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[16]  A. Alberti,et al.  Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure. , 2019, Journal of hepatology.

[17]  Ding‐Shinn Chen,et al.  Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct acting antivirals. , 2019, Journal of hepatology.

[18]  Ding‐Shinn Chen,et al.  Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real‐world effectiveness and safety in Taiwan , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[19]  M. Buti,et al.  Effectiveness and Safety of Sofosbuvir/Velpatasvir/ Voxilaprevir in Patients with Chronic Hepatitis C Previously Treated with DAAs. , 2019, Journal of hepatology.

[20]  B. Pearlman,et al.  Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection. , 2019, The American journal of gastroenterology.

[21]  H. Masur,et al.  A Pilot Study of Safety and Efficacy of HCV Retreatment with sofosbuvir/velpatasvir/voxilaprevir in Patients With or Without HIV (RESOLVE STUDY). , 2019, Journal of hepatology.

[22]  E. Gane,et al.  Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study , 2019, Journal of viral hepatitis.

[23]  Ding‐Shinn Chen,et al.  Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan , 2018, PloS one.

[24]  M. Kumar,et al.  APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? , 2018, Hepatology International.

[25]  M. Manns,et al.  No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients. , 2018, Journal of hepatology.

[26]  J. Kao,et al.  Comorbidities, concomitant medications and potential drug‐drug interactions with interferon‐free direct‐acting antiviral agents in hepatitis C patients in Taiwan , 2018, Alimentary pharmacology & therapeutics.

[27]  R. Fontana,et al.  Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  M. Manns,et al.  Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. , 2018, The lancet. Gastroenterology & hepatology.

[29]  E. Deeks,et al.  Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C , 2018, Drugs.

[30]  Ding‐Shinn Chen,et al.  Real‐world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan , 2018, Journal of Gastroenterology and Hepatology.

[31]  T. Asselah,et al.  Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection , 2018, The New England journal of medicine.

[32]  M. Manns,et al.  Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection , 2017, The New England journal of medicine.

[33]  Ding‐Shinn Chen,et al.  Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection , 2017, Open forum infectious diseases.

[34]  G. Ioannou,et al.  Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. , 2016, Gastroenterology.

[35]  V. Soriano,et al.  Prevention and management of treatment failure to new oral hepatitis C drugs , 2016, Expert opinion on pharmacotherapy.

[36]  M. Kumar,et al.  APASL consensus statements and recommendation on treatment of hepatitis C , 2016, Hepatology International.

[37]  T. Asselah,et al.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. , 2015, The New England journal of medicine.

[38]  J. Feld,et al.  Hepatitis C virus infection , 2015, Canadian Medical Association Journal.

[39]  Ding‐Shinn Chen,et al.  Comparison of Abbott RealTime HCV Genotype II with Versant Line Probe Assay 2.0 for Hepatitis C Virus Genotyping , 2015, Journal of Clinical Microbiology.

[40]  Stefan Zeuzem,et al.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[41]  J. Kao,et al.  Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa , 2014, International journal of nanomedicine.

[42]  Eoin Coakley,et al.  Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.

[43]  M. Niemi,et al.  Impact of OATP transporters on pharmacokinetics , 2009, British journal of pharmacology.

[44]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[45]  A. Zanella,et al.  Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels , 2002, Annals of Internal Medicine.